Michel Gasana
Michel Gasana publishes mostly in Infectious Diseases, Epidemiology and Public Health, Environmental and Occupational Health, on topics such as Tuberculosis Research and Epidemiology, Pneumocystis jirovecii pneumonia detection and treatment and Pneumonia and Respiratory Infections.
- World rank
- #2,197,917 of 7,710,434 ranked researchers
- Rank in Rwanda
- #238 of 716
- Works
- 35
- Citations
- 1.1k
- Citations per work
- 30.3
What does Michel Gasana research?
Michel Gasana's work is mostly in Medicine (72%), Health Professions (6%), Economics, Econometrics and Finance (4%).
Their six largest subfields, inside their fields and domains; the grey slice is everything else they publish. The interactive view splits every one of their works down to single topics.
The fields and subfields, with their numbers
- Health Sciences2778.3%
- Medicine2572.1%
- Health Professions26.2%
- Everything else617.6%
- Social Sciences14.1%
- 1Infectious Diseases38% of their works
- 2Epidemiology21% of their works
- 3Public Health, Environmental and Occupational Health8% of their works
- 4General Health Professions6% of their works
- 5Surgery5% of their works
- 6Economics and Econometrics4% of their works
Research topics
- Tuberculosis Research and Epidemiology
- Pneumocystis jirovecii pneumonia detection and treatment
- Pneumonia and Respiratory Infections
- HIV/AIDS Research and Interventions
- Diagnosis and treatment of tuberculosis
- Malaria Research and Control
- Diverse Scientific Research Studies
- Mycobacterium research and diagnosis
Which keywords describe Michel Gasana's research?
The keywords of their largest research topics: Epidemiology, Treatment, Diagnosis, Vaccine, Mycobacterium tuberculosis, Tuberculosis, Antiretroviral Therapy and Pneumocystis.
- Nontuberculous Mycobacteria
- COVID-19
- Artemisinin Resistance
- Pneumococcal Conjugate Vaccine
- Diagnostic Challenges
- Abdominal Tuberculosis
- Pneumocystis
- Tuberculosis
- Vaccine
- Treatment
- Epidemiology
- Diagnosis
- Mycobacterium tuberculosis
- Antiretroviral Therapy
- Pneumonia
- Community-Acquired Pneumonia
- HIV Transmission
- Preexposure Prophylaxis
- Plasmodium falciparum
- Mycobacterium avium
- Pandemic
Size is their works in the topics tagged with each word, from their 8 largest topics. Each links to the topic it comes from most. The words come from the keyword list OpenAlex gives each topic, not from the text of the papers, so a word can appear that none of the papers uses.
All 21 words, with their numbers
- Epidemiology495 topics
- Treatment434 topics
- Diagnosis403 topics
- Vaccine302 topics
- Mycobacterium tuberculosis271 topic
- Tuberculosis271 topic
- Antiretroviral Therapy152 topics
- Pneumocystis101 topic
- Pneumonia101 topic
- Abdominal Tuberculosis51 topic
- Community-Acquired Pneumonia51 topic
- Diagnostic Challenges51 topic
- HIV Transmission51 topic
- Pneumococcal Conjugate Vaccine51 topic
- Preexposure Prophylaxis51 topic
- Artemisinin Resistance41 topic
- Plasmodium falciparum41 topic
- COVID-1931 topic
- Mycobacterium avium31 topic
- Nontuberculous Mycobacteria31 topic
- Pandemic31 topic
Where does Michel Gasana work?
Michel Gasana's main affiliation in the publication record is Rwanda Biomedical Center, Rwanda.
How many publications and citations does Michel Gasana have?
OpenAlex counts 35 works and 1,059 citations for Michel Gasana, an h-index of 17, ranking #2,197,917 of 7,710,434 researchers worldwide on the quality score.
Ranked on field-normalised citation excellence (50%), output (30%) and citations (20%). Counts come from OpenAlex author records, which occasionally merge different people who share a name or split one person into several.
Papers, co-authors, who cited this work and researchers on the nearest topics have tabs of their own, above. Is this your page? Claim it with your ORCID iD, or request a correction or removal.
Discussion
Ask a question or share a note about Michel Gasana. Keep it to the research: no personal attacks, advertising or links. Any reader can report a post, which collapses it for everyone until it is opened.